Eligibility |
General Inclusion Criteria
A patient is deemed suitable for inclusion in the study if the patient has at least one the
following:
1. Juxtarenal or suprarenal AAA, type I-IV thoracoabdominal aortic aneurysms or aortic
arch aneurysms or dissections with diameter =5.0 cm in diameter or 2 times the normal
aortic diameter;
2. Aneurysm with history of growth =0.5 cm/year;
3. Saccular aneurysm with aortic diameter greater than 1.5 times the normal aortic
diameter that is deemed to be at risk for rupture based upon physician interpretation.
4. Patients that are not eligible for treatment with commercially available endografts.
5. Presence of concomitant thoracoabdominal and aortic arch aneurysm meeting one of the
above-mentioned criteria.
General Exclusion Criteria
A patient must be excluded from the clinical investigation if any of the following are
true:
1. Age <18 years;
2. Life expectancy <2 years;
3. Pregnant, breast-feeding, or planning on becoming pregnant within 60 months;
4. Inability or refusal to give informed consent by the patient or a legally authorized
representative;
5. Unwilling or unable to comply with the follow-up schedule;
6. Prior surgical or interventional procedure within 30 days of the anticipated date of
the fenestrated procedure, with the exception of planned staged procedures to provide
access for repair (e.g. staged iliac conduit, thoracic endovascular aortic aneurysm
repair for proximal aneurysms, elephant trunk repair), to facilitate the procedure by
allowing open reparation of a target artery not amenable to revascularization with the
investigational device, such us an internal iliac artery, subclavian artery or
visceral artery with early bifurcation, tortuosity or occlusive disease preventing
successful placement and alignment side stents, or to treat proximal aortic aneurysms.
7. Participation in another clinical or device trial, with the exception of observational
studies, participation in another investigational endovascular endograft protocol,
percutaneous aortic valve protocol, or concomitant clinical trials designed to
evaluate medical therapy strategies to reduce perioperative risk during
fenestrated-branched endovascular repair, including risks of renal dysfunction,
contrast-induced nephropathy, neurologic, spinal cord or cardiac complications, and/or
use of advanced imaging to reduce radiation exposure during implantation of these
devices. Participation in investigational device trials not encompassed by the IDE
protocol should be performed remotely from the fenestrated/branched repair (>30 days).
Participation in medical therapy trial or advanced imaging trial designed to improve
peri-operative outcomes or to reduce radiation exposure of fenestrated/branched
endografts may be concurrent with the IDE study. Examples include therapy directed to
reduce rates of spinal cord injury, stroke and contrast-induced nephropathy associated
with implantation of fenestrated-branched stent-grafts or advanced imaging trials
designed to reduce radiation exposure during repair.
8. Patients with ruptured aortic aneurysm requiring urgent or emergent repair, with the
exception of patients with contained, stable ruptures with anatomy suitable for an
off-the-shelf design.
9. Patients who meet anatomical criteria for commercially available aortic stent-grafts
according to proposed instructions for use of these devices.
Medical Exclusion Criteria
Patients must be excluded from the study if any of the following conditions are true:
1. Known sensitivities or allergies to stainless steel, nitinol, polyester, solder (tin,
silver), polypropylene, urethane or gold
2. History of anaphylactic reaction to contrast material that cannot be adequately
pre-medicated
3. Leaking or ruptured aneurysm associated with hypotension
4. Uncorrectable coagulopathy
5. Mycotic aneurysm or patients with evidence of active systemic infection.
6. History of connective tissue disorder (e.g. vascular Ehlers Danlos, Marfan syndrome),
with the exception of those patients who had prior open surgical aortic replacement or
endovascular repair, where a surgical graft or an endograft would serve as landing
zone for the investigational endograft, those who are deemed prohibitive risk for open
repair or connective tissue disorders with no vascular effects (e.g. non-vascular
types of Ehlers Danlos).
7. Body habitus that would inhibit x-ray visualization of the aorta and its branches.
Anatomical Exclusion Criteria
Patient must be excluded from the study if any of the following is true:
1. Inadequate femoral or iliac access compatible with the requirements of the required
delivery system.
2. Inability to perform a temporary or permanent open surgical or endovascular iliac
conduit for patients with inadequate femoral/iliac access.
3. Absence of a landing aortic segment in the distal thoracic aorta above the
diaphragmatic hiatus with:
1. A diameter measured outer to the outer wall greater than 42 mm or less than 19
mm;
2. Parallel aortic wall with >20% diameter change and with significant calcification
and/or thrombus in the selected area of the seal zone.
4. Visceral anatomy not compatible with the investigational device due to excessive
occlusive disease or small size not amenable to stent graft placement.
5. Unsuitable distal iliac arterial fixation site and anatomy:
1. Common iliac artery fixation site diameter measured outer wall to outer wall on a
section image (CT)< 8.0 mm with inability to perform surgical conduit.
2. Iliac artery diameter measured outer wall to outer wall on a sectional image (CT)
> 21 mm at distal fixation site, with inability to perform open internal iliac
artery revascularization or iliac branch stent graft or custom iliac extension
with fenestration.
3. Iliac artery distal fixation site <10 mm in length.
4. Inability to preserve at least one hypogastric artery.
For patients in the type I-III TAAA cohort, the intended use criteria are the same for both
the fenestrated/branched CMD vs the off-the-shelf device. The CMD will preferably be used,
unless an urgent repair is indicated or the waiting period for design or manufacturing of
the CMD is considered unacceptable.
Additional anatomical inclusion criteria for aortic arch devices
1. Proximal aortic fixation zone:
1. Native aorta or surgical graft
2. Diameter: 20-42mm
3. Proximal neck length = 20mm
4. Ascending aortic length =50mm
5. Must occur distal to coronary arteries and any coronary artery bypass grafts that
are considered patent and necessary for proper cardiac perfusion
2. Distal aortic fixation zone:
1. Native aorta or surgical graft
2. Diameter: 20-42mm
3. Distal neck length =20mm
4. Distal fixation will be obtained with stent-grafts in a staged repair
3. Supra-aortic trunk (brachiocephalic) vessels
1. The arch branch device will typically have two or three branches with additional
modifications to the design that allows for a single branch or combination of
branch and scallop if a customized version is required. An extra-anatomic bypass
graft may be done in conjunction (or in a staged fashion) with the procedure, as
required. For the two-branch design, the vessels most commonly incorporated will
be the innominate artery and left common carotid artery. However, the innominate
artery may be coupled with the left subclavian artery in the setting of a bovine
arch whereby the flow to the left carotid would come from a left subclavian to
carotid bypass. Similarly, the left carotid and subclavian artery may be
branched, or simply one vessel branched should specific anatomic limitations
exist. In such a situation, multiple extra-anatomic bypasses may be necessary. A
design with a single subclavian retrograde branch and scallop to the left carotid
artery may be used to extent the landing zone to Zone 1. Finally, a design with
two antegrade inner branches for the innominate and left common carotid, and one
retrograde inner branch for the left subclavian artery may be used in select
cases. Thus, the inclusion criteria are defined for each artery, yet any
combination of arteries may be used for a repair.
i. Innominate artery
1. Native vessel or surgical graft
2. Diameter: 8-22mm
3. Length of sealing zone =10mm
4. Acceptable tortuosity
ii. Left (or right) common carotid artery
1. Native vessel or surgical graft
2. Diameter 6-16mm
3. Length of sealing zone =10mm
4. Acceptable tortuosity
iii. Left (or right) subclavian artery
1. Native vessel or surgical graft
2. Diameter: 5-20mm
3. Length of sealing zone =10mm
4. Acceptable tortuosity
4. In the setting of an aortic dissection the following criteria must exist:
1. Access into the true lumen from the groin and at least one supra-aortic trunk vessel
2. A sealing zone in the target aorta (or surgical graft) that is proximal to the primary
dissection, such that a stent-graft would be anticipated to seal off the dissection
lumen
3. A sealing zone in the target supra-aortic trunk vessels that is distal to the
dissection, anticipated to seal off the dissection lumen, or surgically created
4. A true lumen size large enough to deploy the device and still gain access into the
target branches
5. In the setting of more distal disease, the repair may be coupled with a
thoracoabdominal branched device, infrarenal device, and/or internal iliac branch
device.
6. Iliac anatomy must allow for the delivery of the arch branch device which is loaded
within a 20F-24F sheath. Conduits to the iliac vessels or aorta may be used if deemed
necessary.
|